Braftovi and Blindness - a phase IV clinical study of FDA data

Summary:

Blindness is reported as a side effect among people who take Braftovi (encorafenib), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Mektovi, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Blindness when taking Braftovi. It is created by eHealthMe based on reports of 7,606 people who have side effects when taking Braftovi from the FDA, and is updated regularly.

What is Braftovi?

Braftovi has active ingredients of encorafenib. eHealthMe is studying from 7,609 Braftovi users. Check the latest studies of Braftovi.

What is Blindness?

Blindness is found to be associated with 1,508 drugs and 1,987 conditions by eHealthMe. Check the latest studies of Blindness.

On Jul, 26, 2026

7,606 people reported to have side effects when taking Braftovi.
Among them, 30 people (0.39%) have Blindness.

Among these 30 people:

How long have people been on Braftovi when they have Blindness? *

What is the gender of people who have Blindness when taking Braftovi? *

female: 45.45 %
male: 54.55 %

What is the age of people who have Blindness when taking Braftovi? *

What are other drugs people take besides Braftovi? *

What are other side effects people have besides Blindness? *

Diarrhea: 5 people, 16.67%
Abdominal Distension: 4 people, 13.33%
Dehydration (dryness resulting from the removal of water): 4 people, 13.33%
Visual Impairment: 4 people, 13.33%
Rashes (redness): 4 people, 13.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 10.00%
Vision Blurred: 3 people, 10.00%
Reading Disorder (problem in areas of the brain that help interpret language): 3 people, 10.00%
Eating Disorder: 3 people, 10.00%
Retching (strong involuntary effort to vomit): 3 people, 10.00%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 13 people, 43.33%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 10.00%
Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously): 1 person, 3.33%
Papillary Thyroid Cancer: 1 person, 3.33%
Neoplasm Malignant (cancer tumour): 1 person, 3.33%
Metastasis (spreadable cancer to other organ from origin): 1 person, 3.33%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 1 person, 3.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 3.33%
Hyperplasia (enlargement of an organ or tissue): 1 person, 3.33%
High Blood Pressure: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Braftovi and have Blindness?

- Check whether Blindness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Braftovi:

Braftovi (7,609 reports)

Blindness treatments and more:

Blindness (45,948 reports)

Browse all side effects of Braftovi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Blindness:

Blindness (1,508 drugs)

Browse all the conditions that are associated with Blindness:

Blindness (1,987 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on encorafenib (the active ingredients of Braftovi) and Braftovi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.